Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.

被引：0
|
作者：
Dong, Wei [1 ]
Zhang, Songyan [1 ]
Huo, Zhuoni [1 ]
Lu, Junrong [1 ]
Liu, Haishi [1 ]
Wang, Ping [1 ]
Zhang, Yubao [1 ]
机构：
[1] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16160
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant PD-1 blockade in combination with chemotherapy for patients with resectable esophageal squamous cell carcinoma
    Cheng Chao
    Yang Weixiong
    Chen Wenfang
    Yeung, Sau-Ching Jim
    Xing Xiangbin
    Wang Xiaoyan
    Bao Yong
    Feng Shiting
    Peng Fang
    Liu Zhenguo
    Zeng Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [42] Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma
    Yuan, Wei
    Yue, Wenchao
    Wen, Huabing
    Wang, Xueqin
    Wang, Qi
    EUROPEAN SURGICAL RESEARCH, 2023, 64 (02) : 268 - 277
  • [43] Hepatic Arterial Infusion Chemotherapy for Patients with Huge Unresectable Hepatocellular Carcinoma
    Tsai, Wei-Lun
    Lai, Kwok-Hung
    Liang, Huei-Lung
    Hsu, Ping-I
    Chan, Hoi-Hung
    Chen, Wen-Chi
    Yu, Hsien-Chung
    Tsay, Feng-Woei
    Wang, Huay-Min
    Tsai, Hung-Chih
    Cheng, Jin-Shiung
    PLOS ONE, 2014, 9 (05):
  • [44] Hepatic-arterial infusion chemotherapy for patients with advanced hepatocellular carcinoma
    Yamashita, T.
    Arai, K.
    Kitamura, K.
    Iida, H.
    Kagaya, T.
    Mizukoshi, E.
    Sakai, A.
    Kaneko, S.
    LIVER INTERNATIONAL, 2006, 26 : 66 - 66
  • [45] Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer
    Zhang, Ting
    Zhu, Chengpei
    Zhang, Nan
    Zhang, Longhao
    Wang, Shanshan
    Xun, Ziyu
    Xu, Yiyao
    Yang, Xiaobo
    Lu, Xin
    Zhao, Haitao
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 129
  • [46] Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis
    Yizhen Fu
    Wei Peng
    Weixiang Zhang
    Zhenyun Yang
    Zili Hu
    Yanxun Pang
    Dandan Hu
    Jinbin Chen
    Juncheng Wang
    Zhongguo Zhou
    Li Xu
    Minshan Chen
    Yaojun Zhang
    Journal of Gastroenterology, 2023, 58 : 413 - 424
  • [47] Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis
    Fu, Yizhen
    Peng, Wei
    Zhang, Weixiang
    Yang, Zhenyun
    Hu, Zili
    Pang, Yanxun
    Hu, Dandan
    Chen, Jinbin
    Wang, Juncheng
    Zhou, Zhongguo
    Xu, Li
    Chen, Minshan
    Zhang, Yaojun
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (04) : 413 - 424
  • [48] Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma.
    Shi, Feng
    Peng, Zhenwei
    Xia, Dongdong
    Mai, Qicong
    Wang, Meng
    Mei, Jie
    Kuang, Ming
    Chen, Xiaoming
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 580 - 580
  • [49] Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
    Jia, Meng
    Jia, Jiang-Kun
    Xu, Jian
    Xue, Huan-Zhou
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2625 - 2638
  • [50] Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
    Luo, Laihui
    Xiao, Yongqiang
    Zhu, Guoqing
    Huang, Aihong
    Song, Shengjiang
    Wang, Tao
    Ge, Xian
    Xie, Jin
    Deng, Wei
    Hu, Zhigao
    Wen, Wu
    Mei, Haoran
    Wan, Renhua
    Shan, Renfeng
    FRONTIERS IN ONCOLOGY, 2022, 12
12345